Altay Therapeutics has closed a $37 million Series A financing to advance DX5057, an investigational oral DUX4 inhibitor for facioscapulohumeral muscular dystrophy. The company expects to begin Phase 1 testing in early 2027, following preclinical evidence of reduced muscle injury and preserved function.
Soufflé secures $135 million as its FSHD RNA therapy trial recruits patients. Examine the REMEDY platform, Bayer partnership and clinical risks.
A peer-reviewed five-year indirect comparison associates BRIUMVI with lower modeled disability progression risk than ocrelizumab and ofatumumab. The findings support TG Therapeutics' commercial evidence strategy but cannot establish head-to-head superiority.
Bristol Myers Squibb's RYZ101 meets its Phase 3 endpoint after lutetium-177 treatment, advancing alpha radiopharmaceutical development.
GSK expands Chai Discovery AI collaboration after wet-lab success. See what the binding results establish and what remains unproven.
Perceptive Discovery and Nucleus RadioPharma link imaging and manufacturing to address critical bottlenecks in radiopharmaceutical development.
FDA approves Novartis Rhapsido as the first treatment specifically for symptomatic dermographism after positive Phase III RemIND results.
The FDA has accepted Roche’s fenebrutinib filing under Priority Review for both relapsing and primary progressive multiple sclerosis, potentially creating a high-efficacy oral alternative across disease forms currently treated very differently.
European regulators have approved AstraZeneca’s Trixeo Aerosphere for uncontrolled asthma from age 12 regardless of recent exacerbation history, potentially widening a respiratory franchise that generated $699 million in first-half 2026 sales.
Roche’s sefaxersen hits its Phase III IgAN endpoint with significant proteinuria reduction. See what the result means for regulators and competitors.